Milameline

In the world of Milameline, there have been countless significant developments and changes over the years. Since its inception, Milameline has captured the attention and intrigue of people of all ages and interests. Studies and discoveries related to Milameline have been a source of fascination and debate, and continue to have a significant impact on the world today. As society evolves, so does the role and relevance of Milameline, making it an extremely relevant and interesting topic to explore and understand in depth. In this article, we will explore the importance and evolution of Milameline, as well as its meaning and impact today.

Chemical compound

Milameline

Clinical data
ATC code	None
Identifiers
IUPAC name (E)-N-methoxy-1-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methanimine
CAS Number	139886-32-1
PubChem CID	9571002
IUPHAR/BPS	301
ChemSpider	7845468
UNII	R9X77R42FN
ECHA InfoCard	100.220.595
Chemical and physical data
Formula	C8H14N2O
Molar mass	154.213 g·mol−1
3D model (JSmol)	Interactive image
SMILES N(/OC)=C\C1=C\CCN(C)C1

Milameline (CI-979, PD-129,409, RU-35,926) is a non-selective muscarinic acetylcholine receptor partial agonist with cognition-acting properties that was being investigated for the treatment of Alzheimer's disease, but produced poor results in clinical trials and was subsequently discontinued.

• Changing the O-methyl aldoxime to an O-propargyl oxime instead gives a separate molecule called RU 35986.

See also

• Alvameline
• Sabcomeline
• Tazomeline
• Xanomeline

References

1. ^ Sedman AJ, Bockbrader H, Schwarz RD (1995). "Preclinical and phase 1 clinical characterization of CI-979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease". Life Sciences. 56 (11–12): 877–882. doi:10.1016/0024-3205(95)00023-Y. PMID 10188788.
2. ^ Broadley KJ, Kelly DR (2001). "Muscarinic Receptor Agonists and Antagonists". Molecules. 6 (3): 142–193. doi:10.3390/60300142. ISSN 1420-3049. PMC 6236374.